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ABSTRACT 
Bone morphogenetic proteins (BMPs) heal nonunions of long bone. In a randomized and 
controlled pilot study we tested the effect of osteogenic protein-1 (OP-1, BMP-7) on healing 
of avascular necrosis of the scaphoid proximal pole non-union.  
17 patients with proximal pole bone non-union and pre-existing sclerotic bone were randomly 
assigned to one of three groups: (1) Autologous iliac graft (n=6), (2) Autologous iliac graft + 
OP-1 (n=6) and (3) Allogeneic iliac graft + OP-1 (n=5). Radiographic, scintigraphic and 
clinical assessment was performed throughout the follow-up period of 24 months. 
OP-1 improved the performance of both autologous and allogeneic bone implants and reduced 
radiographic healing time to 4 weeks as compared to 9 weeks in the autologous bone only 
treated group. Helical CT scans and scintigraphy showed that the pre-existing sclerotic bone 
within proximal scaphoid poles was mainly replaced in OP-1 treated patients with well 
vascularized bone. Addition of OP-1 to allogeneic bone implant equalized the clinical 
outcome with the autologous graft procedure and enabled circumventing the second donor 
graft harvest procedure.  
This is the first evidence that a recombinant BMP enhances radiographic healing of the 
scaphoid non-union and revascularization and removal of pre-existing sclerotic bone from the 
proximal pole avascular necrosis. 
 
 
 
 
 
 
 
 3 
INTRODUCTION 
Scaphoid fracture is the most common carpal bone fracture [4]. Approximately 5%-10% 
scaphoid fractures proceed to a non-union [13]. Although initially asymptomatic, most 
nonunions progress to produce a painful wrist with impaired function, clinically significant 
loss of motion, increased weakness and degenerative arthritis [18]. The treatment of scaphoid 
non-union still remains a problem considering its vulnerable blood supply, irregular shape, 
special oblique alignment across the motion plane of the mid-carpal joint and complex 
function linking proximal and distal carpal rows [8]. Bone graft with or without internal 
fixation by a screw or wires is the standard treatment for symptomatic scaphoid non-unions 
without osteoarthritis [10, 21, 23, 25]. Cancellous bone grafting, first described by Matti and 
modified by Russe is the most common surgical treatment [6], requiring approximately 13 
weeks for scaphoid non-union to heal. Modified Matti-Russe procedure by Bilic, using 
compressed cancellous bone grafting, requires approximately 9 weeks to heal scaphoid 
pseudoarthroses [1].  These techniques achieve union in 70-90% of patients and the type of 
fracture and the vascularity of the proximal pole are important determinants of the success of 
therapy [9]. Recent meta analysis of scaphoid nonunion literature indicate a 94% success rate 
in unstable nonunions treated with a screw fixation and grafting, but only 47% in patients 
with concomitant avascular necrosis [15]. Therefore we have tried to improve the treatment of 
scaphoid bone non-union with avascular pole necrosis by use of bone morphogenetic proteins 
(BMPs). 
Bone morphogenetic proteins (BMPs) or osteogenic proteins (OPs) are growth and 
differentiation factors capable of initiating the recruitment, attachment, proliferation and 
differentiation of mesenchymal cells, leading to new bone formation [14, 24]. Extensive 
clinical and preclinical research has been undertaken to investigate the role of OP-1 (BMP-7) 
in bone and cartilage regeneration [17]. OP-1 heals critical-sized diaphyseal defects and 
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nonunions of long bones, enhances bone graft incorporation and implant fixation, increases 
remodeling and bone ingrowth of bone grafts and bone substitutes [3, 5, 7, 14].  
The aim of this pilot study was to test if the recombinant BMP-7 (osteogenic protein – 1; OP-
1), a signaling molecule for initialing osteogenesis [14], could enhance radiographic and 
clinical healing and removal of sclerosis in scaphoid non-unions containing sclerotic bone.  
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MATERIALS AND METHODS 
The study design  
The criteria for inclusion in the study comprised male or female patients between ages of 15 
and 30 years with a symptomatic proximal pole scaphoid non-union for at least 9 months of 
duration with no evidence of progressive healing over the previous 3 months, and a presence 
of 100 mm2 or more pre-existing sclerotic bone in the proximal scaphoid pole as determined 
preoperatively by spiral CT. Study exclusion criteria comprised patients with: prior surgical 
treatment, carpal collapse, immature skeleton and unable or unwilling to fulfill the follow-up 
requirements. One hundred and thirty nine patients were screened for scaphoid non-unions in 
the period from January 1999 till January 2003 in the Department of Orthopedic Surgery, 
University of Zagreb.  
Patients were randomly assigned to one of the treatment groups using a computer-generated 
randomization. The cohorts were defined as follows: 1. Autologous iliac graft only (n=6), 2. 
Autologous iliac graft + OP-1 (n=6), and 3. Allogeneic iliac graft + OP-1 (n=6). The study 
was performed in compliance with the Helsinki Declaration and fulfilled the consort 
statement requirements [16]. The bone grafts were prepared according to modified Matti-
Russe procedure by Bilic [1] using compressed iliac bone, showing better compaction as 
compared to radial spongiosa. Surgeons were aware of the treatment group to which each 
patient was assigned after the random selection process. At 2 months following surgery and 
removal of the cast physical therapy was introduced and included active exercise of the wrist 
and fingers, as well as supported and passive exercise.  
Demographics 
The demographics of the study groups is presented in Table 1. Three randomly assigned 
groups of young men were similar (P>0.05) in many respects, including age, body mass 
index, duration of non-union, fracture site, direction of fracture line, and area of proximal pole 
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sclerosis. The mean time from original injury to treatment of scaphoid nonunion was 14 
months (range 9 - 20 months). All patients had pain and weakness, loss of motion, decreased 
grip strength and fatigue with repetitive work. In most patients, preoperative motion was 
restricted and grip strength was decreased to a mean of 62%.  
 
OP-1 Implant  
The OP-1 Implant (Osigraft) composed of 3.5 mg recombinant human OP-1 (BMP-7) and 1 
gram of collagen as a carrier was obtained from Stryker Biotech (Hopkinton, Massachusetts). 
The OP-1 implant was applied to both scaphoid fragments and subsequently autogenous or 
allogeneic bone implants were positioned as per Mati-Russe technique. 
 
Methods of clinical assessment   
The clinical evaluation included the presence of pain assessment by visual analogous scale 
during rest, at maximal grip strength and at maximal dorsal flexion of the wrist. Additionally, 
measurements of movements in radiocarpal joint, strength of the grip and strength of the 
pinch on both hands were assessed. Patients were clinically evaluated after removal of a post 
operatively applied cast, no later than 2 months post operatively, and thereafter at 2, 4, 5, 9, 
12 and 24 months. Physical therapy started following removal of the cast. In addition, date 
and details of original injury, previous treatments, body mass index and smoking status were 
also recorded.  
 
Radiographic analysis 
1. Union was assessed on X-rays utilizing plain film in four views. 
Radiographs of both hands were taken prior to surgery, of affected hand immediately 
following surgery, and then 1, 2, 2.5 or 3 (2.5 if the healing was more than 75% and 3 months 
 7 
if less than 75%), 4, 9 and 24 months following surgery. X-rays were evaluated by two 
radiologists, blinded to treatment and time following the surgical procedure, assessing 
whether 0-33, 34-66 or 67-100 percent of the scaphoid bone surface remodeled healed. 
Healing of the regenerating scaphoid bone reflects a gradual replacement of the graft by 
newly formed and well incorporated bone, including its full mineralization in time.  
 
Computerized tomography 
Helical CT scans were used to assess preoperatively the amount of proximal pole sclerotic 
bone since only patients with more than 100 mm2 of sclerotic bone area have been randomly 
included into the study. Pre-existing sclerotic bone from the proximal scaphoid pole was 
measured by the helical CT software (AW 4.2 General Electric Medical System – GEMS) and 
then manually confirmed by a planimeter on multiple CT sections taken immediately 
following the surgery. Bone was also tested during the surgery and was considered sclerotic 
and avascular by demonstration of the absence of punctuate bleeding from the fragments on 
exposed bone. CT of the affected hand was taken prior to surgery, immediately following 
surgery, and then at 3, 9, 12 and 24 months following surgery. Proximal pole sclerotic bone 
removal was assessed by blinded interpretation of CT scans to assess the efficacy of a single 
application of BMP-7 (administered with an auto- or allograft) as compared to autograft 
treatment alone. Sections were made at 0.6 mm intervals [19]. 
 
Three-phase bone scintigraphy 
To additionally assess removal of sclerotic pre-existing bone by new blood vessels, patients 
were subjected to three-phase 99m Tehnetium-dicarboxypropane diphosphonate  (99mTc-
DPD) scintigraphy prior to surgery and then at 24 months following surgery. The 
angiographic phase (0-60 sec post injection) was acquired in dorsal projection after bolus 
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injection of 600 MBq 99mTc-DPD. The blood pool phase of the tracer was investigated 10-20 
min following injection and bone uptake phase 3 h following injection. Bone scans of 
radiocarpal joint of the operated and healthy hands were obtained with a LFOV gamma-
camera (Siemens, DIACAM) in the dorsal position. The affected area was measured 
planimetrically.  
 
Data analysis  
Distributions of all quantitative data were tested with Kolmogorov-Smirnov test. In spite of 
small sample sizes all distributions conform to normal distribution, hence parametric 
analytical procedures were applied. Demographic data and functional measurement data 
within the same time point were analyzed with One way ANOVA with one-sided Dunett t 
post hoc test against autograft only treated patients. Sclerotic bone area changes were 
analyzed with two way ANOVA for repeated measurements with Shaffe post hoc test. 
Analysis was performed using the STATISTICA computer program, version 6.0 (StatSoft, 
Inc., Tulsa, OK, USA).                   
 
 
RESULTS 
 
Radiographic results 
One patient who received the allogeneic bone and OP-1 was lost for the follow up (Table 1). 
The scaphoid nonunion in the remaining 17 patients healed as assessed by conventional x-
rays and CT analysis (Figure 1). Four weeks following the surgery 70%-95% of bone in 
autograft + OP-1 patients demonstrated radiographic bridging as compared to 60%-80% in 
both allograft + OP-1 and autograft only treated patients (p<0.05). At 4 weeks radiographic 
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data could not be correlated to clinical parameters since the hand was still immobilized. At 8 
weeks following surgery 90%-100% of bone in autograft + OP-1 patients showed 
radiographic bridging as compared to 75%-90% in both allograft + OP-1 and autograft only 
treated patients (not significant). 
Between all follow up time points within each treatment group statistically significant 
decrease of sclerotic bone area has been observed (Table 2, Figure 2). Steeper loss of sclerotic 
bone area was demonstrated in patients treated with OP-1 as compared to autograft only in the 
first and last follow up period. On the contrary, between 3 – 12 months of follow up the loss 
of sclerotic bone area was similar in all groups of patients. At 24 months follow-up nonunion 
fractures healed in all 17 patients.  However, the sclerotic bone almost fully disappeared in 
autograft and OP-1 treated patients (Table 2, Figure 2E) as compared to autograft only treated 
patients (Table 2, Figure 2B), indicating an accelerated process of sclerotic bone resorption 
following full restoration of bone integrity (Table 2, Figure 2E). In patients treated with 
allogeneic bone and OP-1 an increased and transient radiolucency along the graft was 
observed at 8 weeks following surgery (Figure 1 G-I), which did not influence the clinical 
outcome as evidenced by functional clinical tests (Table 3). At 24 months following surgery 
(Figure 2F) the pre-existing sclerotic bone of allogeneic bone and OP-1 treated patients was 
also significantly reduced as compared to autograft only treated patients (Table 2). 
 
Clinical outcome 
Patients in both autologous iliac bone group and autologous iliac bone and OP-1 had pain at a 
donor site following surgery. Those treated with allogeneic bone and OP-1 had approximately 
50 ml less blood loss due to the lack of second operation and had no pain at the pelvic site. 
Additionally, these patients were exposed to anesthesia 95 min as compared to 140 min of 
patients undergoing both operations. There were no reported adverse events.  Patients in all 
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three groups showed improvement of functional measurements and clinical outcome 
throughout the period of 24 months (Table 3). Four months following surgery, patients treated 
with autologous bone and OP-1 reached about 91% of functional values of the non-affected 
hand and had statistically significant improvement in functional measurements of ulnar and  
radial deviation, palmar and dorsal flexion, pinch strength and pain during maximal 
dorsiflexion and during maximal grip as compared to autograft only treated group of patients 
(Table 3). Patients treated with allogeneic bone and OP-1 showed about 85% of function of 
the healthy hand and had significantly improved radial deviation and pain during maximal 
grip at 4 months following surgery as compared to patients treated with autologous bone only. 
There were no statistically significant differences in functional tests between patients treated 
with autologous bone and OP-1 and those treated with allogeneic bone and OP-1. Patients 
treated with autologous bone graft had 75% of healthy hand function. Two years following 
surgery patients in all three treatment groups had good functional results. Patients treated with 
allogeneic bone and OP-1 had reduced pain during maximal grip as compared to autograft 
only treated patients.  
 
Scintigraphic results 
Patients subjected to scintigraphic analyses by 99mTc had normal perfusion during the 
arterial phase, without signs of infection. Blood pool image showed increased uptake in 
patients treated with OP-1 corresponding to formation of new vascular spaces and bone 
marrow, while in control patients normal blood-pool image probably corresponds with stabile 
phase. The late bone scans showed higher tracer uptake in patients treated with OP-1 and 
bone graft, as compared to patients treated only with autologous bone (4.86 in autograft+OP-
1, 4.57 in allograft+OP-1 and 3,26 cm2  in autograft only treated patients, P<0.05) (Figure 2), 
suggesting increased bone vascularity and metabolic activity in OP-1 treated scaphoids. Both 
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groups of patients showed increased tracer uptake in the affected hand as compared to the 
healthy hand (Figure 2). These results confirm that OP-1 added to both autologous and 
allogeneic bone graft accelerated vascular ingrowth and subsequent replacement of pre-
existing sclerotic bone (Figure 2 E and F).  
 
DISCUSSION 
The results of this pilot study demonstrate that a recombinant human OP-1 (BMP-7) supports 
proximal pole scaphoid non-union healing via increased bone vascularization and replacement 
of pre-existing proximal pole sclerotic bone as a consequence of avascular necrosis. OP-1 
enhances radiological healing of scaphoid non-unions in autologous bone treated patients, 
reducing the healing time to 4 weeks as compared to 9 weeks in the autologous bone only 
treated patients. Potential shortening of the immobilization period by OP-1 might 
considerably reduce the incidence of arthritic changes in radioscaphoid and radiocarpal joints, 
contractures of immobilized joints and eventually the Sudeck’s dystrophy. This is also a way 
of preventing muscular atrophy of the forearm and hand, enabling patients to return earlier to 
work. Patients treated with allogeneic bone implant and OP-1 showed radiographic healing 8 
weeks following surgery, which was comparable to autologous bone only treated patients, 
suggesting that autologous bone implant could be replaced when allogeneic bone implant is 
used in combination with OP-1. The use of autogenous iliac graft is linked to side-effects by 
the nature of a donor site, leading to increased operative blood loss, postoperative pain at the 
donor site and increased probability of infection. Furthermore, addition of OP-1 to both 
autologous and allogeneic bone significantly improves functional performance of the affected 
hand as compared to autologous treatment only.  
Despite extensive experience the treatment of scaphoid fracture is still a difficult problem. 
The worst healing rate has been described in patients with avascular necrosis of the proximal 
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fragment (47%), with an option of vascularized bone grafting implantation which leads to 
questionable results [15, 22]. Since OP-1 enhanced the vascular ingrowth into the scaphoid, 
more precursor cells became available to this specific environment resulting in accelerated 
removal of sclerotic bone of the proximal pole in patients treated with OP-1. Up to now, 
BMPs have been successfully tested in clinical trials and subsequently approved for treating 
long bone non-unions [7], acute fractures [12] and spinal fusions [2].  
The likelihood of healing scaphoid non-unions was decreased in our patients due to delayed 
time between injury and the operation of the non-union, avascular necrosis of the proximal 
pole, which normally has a poor blood supply (Table 1). As scaphoid branches of the radial 
artery supply about 70-80% of bone, fractures separating the proximal pole, which is 
completely covered with hyaline cartilage, leads to roughly 30-40% necrosis following this 
type of fracture [20]. Successful outcome in these patients due to addition of OP-1 was 
achieved in part by increased vascular ingrowth resulting in accelerated removal of sclerotic 
bone from the proximal scaphoid poles. Enhanced vascularization enabled both greater 
number of preosteoblasts and preosteoclasts to reach this specific environment. Contrary to 
outcome of this study, it was reported that purified native BMP and iliac crest bone along 
with a biocoral or screw fixation in the treatment of scaphoid nonunions [11] resulted in poor 
clinical results eventually due to compromised avascular environment which prevented access 
of the native BMP and stem cells. This resulted in inadequate resorption of biocoral implants. 
The controlled dosing and pronounced angiogenic effect with recombinant human BMP as 
compared to purified bovine BMP may explain the different outcome in the two studies.  
Timely application of OP-1 in treating scaphoid fractures may thus prevent development of 
avascular necrosis and subsequent osteosclerosis and help restoring normal bone structure by 
simulating removal and replacement of sclerotic bone. 
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This study has also shown that application of OP-1 with an allograft results in healing of the 
scaphoid non-union as well. Use of an allograft from the donor’s iliac crest avoids the 
autograft donor site morbidity which includes less bleeding, less pain, less infection possibilty 
and shorter procedure. 
In conclusion, this clinical study demonstrated that recombinant BMP resulted in a 
radiological and clinical repair of a scaphoid avascular and necrotic proximal pole non-
unions. The results of this study serve also as a hope for patients with avascular necrosis of 
the femoral head which is one of the most challenging, yet unsolved orthopedic problems. 
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Table 1. Patient demographics  
          Study groups 
  
OP-1 + autograft 
n=6 
Autograft only 
n=6 
OP-1 + allograft 
n=5 
Non-union duration (months)+ 15±5 14±5 13±4 
Fracture site (proximal / middle / distal) 1/3/2 1/4/1 1/3/1 
Proximal pole sclerosis CT area (>100 mm2) 6 6 5 
Age (years)+ 23±5 22±5 19±4 
Body mass index (kg/m2)+ 20,1±1,5 21,3±2,1 19,8±1,3 
Tobacco 3 3 2 
ANOVA analysis of duration, age and body mass index was not different between patient cohorts 
+ mean±SD 
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Table 2. Sclerotic bone areas as assessed by CT 
  
Sclerotic area (mm2) 
(range) 
 
Immediately 
following surgery 
3 months following 
surgery 
9 months following 
surgery 
24 months 
following surgery 
Autograft only 
148.3±11.9 
(136-168) 
138.3±15.1(1) 
(122-160) 
118.8±19.0 
(95-141) 
111.5±8.6 
(103-126) 
Autograft + OP-1 
121.5±12.5 
(111-140) 
74.0±14.1(1) 
(59-93) 
44.7±11.3(2) 
(31-62) 
31.7±6.8* 
(25-40) 
Allograft + OP-1 
133.7±9.2 
(121-144) 
103.6±13.2(1) 
(89-122) 
77.2±7.8(2) 
(69-86) 
55.6±11.7* 
(42-69) 
 
*p<0.05 vs. autograft only 
(1)
 p<0.05 vs. before surgery 
(2)
 p<0.05 vs. 3 months following surgery and p<0.01 vs. before surgery 
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Table 3. Functional measurement of scaphoid non-union healing at 4 and 12 months 
following surgery 
 
      4 months 12 months 
 functional test 
healthy 
hand 
autograft 
only 
autograft 
+ OP-1 
allograft 
+ OP-1 
  
autograft 
only 
autograft 
+ OP-1 
allograft 
+ OP-1 
ulnar deviation+ 
47±6* 
 
38±5 
 
49±5* 
 
40±4 
  
50±5 
 
57±5 
 
58±6 
 
radial deviation+  
30±4* 
 
20±4 
 
29±3* 
 
26±3* 
  
32±3 
 
35±4 
 
34±3 
 
palmar flexion+  
74±9* 
 
52±6 
 
60±6 
 
59±6 
  
70±7 
 
78±8 
 
76±9 
 
dorsal flexion+  
66±7* 
 
46±6 
 
60±5* 
 
55±5 
 
 
67±6 
 
69±6 
 
68±7 
 
grip strength‡       
44±5* 
 
28±4 
 
36±4 
 
31±3 
  
35±4 
 
41±5 
 
37±3 
 
pinch strength‡      
9±2* 
 
6±1 
 
8±2* 
 
6±1 
  
9±2 
 
10±2 
 
9±2 
 
pain in rest# 
0 
 
0 
 
0 
 
0 
  
0 
 
0 
 
0 
 
pain during 
maximal grip # 
0* 
 
5±1 
 
0* 
 
3±1* 
 
 
6±1 
 
3±1 
 
0* 
 
pain in maximal 
dorsiflexion # 
0* 
 
15±2 
 
0* 
 
11±2 
 
  
11±2 
 
6±1 
 
3±1 
 
+
 degrees; ‡ kg 
# Patients were asked to draw a point on a line showing pain from 0 (no pain) to 100 (maximal pain); analogous 
measurement scale. 
*p<0.05 vs autograft only, ANOVA Dunett test 
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FIGURE LEGEND  
Figure 1. Radiograph of a patient (No. 1) treated with autologous bone implant before (A) and 
8 weeks following surgery (B). CT scan at 9 months following surgery is shown in (C). 
Radiograph of a patient (No. 7) treated with autologous bone and OP-1 before (D) and 8 
weeks following surgery (E). CT scan at 9 months following surgery is shown in (F). 
Radiograph of a patient (No. 13) treated with allogeneic bone and OP-1 before (G) and 8 
weeks following surgery (H). CT scan at 9 months following surgery is shown in (I). 
 
Figure 2. Late bone scintigraphy of a patient (No. 1) treated with autologous bone (A), patient 
(No. 7) treated with autologous bone and OP-1 (B) and patient (No. 13) treated with 
allogeneic bone and OP-1 at 24 months following surgery (C). Higher uptake of 99mTc is 
present in surgically treated scaphoids (arrows), as compared to opposite healthy hand (h). 
Increased vascular spaces in OP-1 treated patients (B, C) at 24 months following surgery 
indicate its permanent presence. 3D reconstruction of CT scans of a patient (No. 1) treated 
with autologous bone only (D), patient (No. 7) treated with autologous bone and OP-1 (E) and 
patient (No. 13) treated with allogeneic bone and OP-1 (F) at 24 months following surgery. 
Minimal amounts of sclerotic bone (OS) are present in the proximal pole of the patient (No. 
7) treated with autologous bone and OP-1. 
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